Ahead of Sonic Healthcare’s (ASX.SHL) fiscal 2026 results release in August, we highlight key areas of focus. Critically, we reassess their implications for our longer-term earnings assumptions and retest our key investment thesis on the multinational pathology and Australian radiology group.

Why it matters: Our positive view on Sonic hinges on margin recovery, mainly in pathology units generating 85% of group revenue. Drivers include indexation from July 1, 2025, on a third of pathology tests, synergy realization from the LADR purchase in Germany, and US restructuring benefits.

  • However, the LADR integration is only in its first year of integration, the review of the underperforming US unit is likely to be a multistage exercise with shifting restructuring options, and the margin-dilutive impact of the new NHS contract in the UK may endure for the medium term.
  • Consequently, we downgrade our midcycle group EBITDA margin forecast to 19.4%, from 21.4% previously. This is still above the average 17% level achieved prior to the peak of the covid pandemic, crediting management’s efforts to lift efficiency by leveraging Sonic’s significant scale.

The bottom line: We cut our fair value estimate on narrow-moat Sonic by 16% to $27, reflecting our tempered outlook on midcycle margins. Nevertheless, the shares trade at a 19% discount to our revised intrinsic assessment and yield a solid 5%, 60% franked.

  • Uncertainty surrounding regulatory changes is perennial, most pressingly with respect to the proposed reform of the private fee schedule in Germany, where Sonic generates 25% of group revenue. But adverse regulatory developments hurt smaller competitors more than Sonic.
  • They also drive consolidation to the benefit of Sonic, especially in Australia, Germany, the UK, and Switzerland. Sonic is the pathology market leader with the scale, operating efficiency, balance sheet, and medical leadership culture to take advantage of any negative government funding reforms.

Sonic Healthcare’s longer term margin recovery still expected

Sonic Healthcare provides laboratory medicine/pathology and diagnostic imaging radiology. It is the third-largest private provider of laboratory medicine globally, behind Quest Diagnostics and Labcorp. Strategy focuses on being a low-cost provider and gaining cost advantage over competitors through scale. This has largely been pursued through acquisitions, buying smaller operators to expand its market share in geographies where it operates. The firm emphasizes medical leadership, recognizing referring doctors as the primary customer, focusing on improving their experience and efficiency.

Sonic has grown via acquisitions in multiple regions, first in its home market Australia, where it’s the largest operator with over 40% of the pathology market and 10% of the diagnostic imaging market. Pathology operates under a hub-and-spoke model, whereby multiple collection facilities feeding centralized laboratories, acquisition synergies procurement, and IT integrations mean most acquisitions are accretive.

The same roll-up strategy is used internationally, and Sonic is now the largest private pathology provider in Germany, the UK, and Switzerland, and a major provider in Belgium, New Zealand, and the US. In most international markets, pathology providers face similar pressures, with government reimbursements lagging testing costs. We see consolidation in Europe and the US as likely, as smaller operators are eventually outcompeted by larger providers with lower costs per test.

Sonic is navigating lower testing volumes since the end of the covid-19 pandemic, and higher labor costs fueled in part by postpandemic inflation. Profits peaked at $1.5 billion in fiscal 2022 and more than halved to $0.5 billion in fiscal 2024, similar to fiscal 2018 levels. This, alongside concerns about potential German healthcare and reimbursement reform leading to cuts to payments for pathology tests, has weighed on the shares.

We forecast group profitability improving, driven by rationalization of its US anatomical pathology operations, increasing testing volumes in the UK from its new Watford laboratory, and cost savings from the integration of the acquisition of LADR in Germany.

Bulls Say

  • The business is defensive, providing an essential service, not tied to economic cycles.
  • Sonic has large market shares in most geographies it operates, including being the largest pathology provider in Australia and Europe.
  • Growth is leveraged to long-term tailwinds from an aging population and increasing levels of testing per person.

Bears Say

  • Earnings are tied to government policy and funding, and changes in policy to government rebates for laboratory medicine and imaging.
  • Growth has been in part fueled by acquisitions; improvements in profitability are tied to unlocking synergies and scale benefits from mergers.
  • Returns on invested capital are only modestly above WACC, suggesting the value of any moat is modest.

Get Morningstar’s insights in your inbox